Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study

The aim of this study was to evaluate the efficacy and safety of pemafibrate in people with type 2 diabetes and hypertriglyceridaemia over a 52‐week period. Participants were randomly assigned to receive treatment with placebo or pemafibrate at a dose of 0.2 or 0.4 mg/d for 24 weeks (treatment perio...

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, Eiichi, Yamashita, Shizuya, Arai, Hidenori, Yokote, Koutaro, Satoh, Jo, Inoguchi, Toyoshi, Nakamura, Jiro, Maegawa, Hiroshi, Yoshioka, Narihito, Tanizawa, Yukio, Watada, Hirotaka, Suganami, Hideki, Ishibashi, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617746/
https://www.ncbi.nlm.nih.gov/pubmed/30830727
http://dx.doi.org/10.1111/dom.13686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617746/
https://www.ncbi.nlm.nih.gov/pubmed/30830727
http://dx.doi.org/10.1111/dom.13686

Ejemplares similares